Summary
What is endurance performance?

Main determining factors
The main determinants of aerobic endurance performance are maximal oxygen uptake (VO2max), the lactate threshold (LT) and work economy (C).
[44] These three factors are now generally accepted as key factors in endurance performance [45] [46] [47] and are supported by findings in different studies on VO2max [48;49] , LT [47;48;50;51] and C [47;50;51] . A fourth factor, the lactate turn point (LTP), has also received some attention [52] . Here we consider briefly each factor in turn.
VO2max is a prerequisite but not a sole determining factor
VO 2 max, the maximal oxygen uptake, has traditionally been regarded as the most important measure in endurance performance. According to Fick's Law it is dependent on cardiac output and the arteriovenous oxygen difference. These in turn, are mainly dependent on total blood volume (BV), the main limiting factor of stroke volume, and total body haemoglobin (tHb). However, lung diffusing capacity, heart rate, distribution of the blood volume to working skeletal muscles and arterial O 2 extraction contribute to VO 2 max as well, as reviewed by Joyner et al [45] and Bassett et al [53] and reported by other researchers. [54;55] Heinicke et al [54] demonstrated the relationship between VO 2 max and BV and tHb in endurance disciplines. Training can improve many of the mentioned factors to increase VO 2 max, such as increasing blood volume [56] , and indeed, VO 2 max values of champion endurance athletes are 50-100% greater than those observed in normally active healthy young subjects. [45] That an increase in VO 2 max has a great potential to increase endurance performance was already shown by Buick et al [57] and Brien et al [58] . After autologous red blood cell reinfusion elevating haemoglobin and haematocrit levels in well-trained runners, running performance was significantly increased. Ekblom et al [59] cites [60] to show that a haemoglobin increase irrespective of baseline haemoglobin levels will increase maximal aerobic power and therefore performance. However, the last statement in this paper by Ekblom et al is at least as important, where the authors warn against extrapolating this finding to the physically fit athlete, as in these subjects other factors than haemoglobin and maximal aerobic power may play a limiting role in performance. Later research emphasized this warning, as VO 2 max was found not to be the only determinant of endurance performance and more emphasis has recently come to the other two factors described by Pate and Kriska. VO 2 max, although a prerequisite to perform at a high level [48] , has a very limited predictive value for endurance performance within a group of high-performance athletes. [61] [62] [63] [64] [65] [66] [67] Also, although successful endurance athletes reached a high VO 2 max after initial years of training, they subsequently maintain a plateau in their VO 2 max but continue to improve further their performance [47;68;69] (note that one of these reports [69] is about Armstrong). Research into training for endurance performance shows the same trend: moderately trained athletes are able to improve VO 2 max (as well as LT and C) by interval and/or intensive training [70;71] , whereas these training regimens do not improve VO 2 max in well-trained athletes, but mainly improve the LT and C [50;72] , possibly by improving buffering capacity [73] .
It is more than the VO2max
It is not VO 2 max, but power output at submaximal intensities such as the first (VT1) and second (VT2) ventilation threshold, or respiratory compensation point (RCP) that significantly differ between elite amateur and professional cyclists. [64;74] Thus factors other than VO 2 max play an important role in determining performance in professional and world-class cyclists. For example, when a published model [75] for predicting endurance performance is used to predict the 1-hour cycling world record as described by Padilla et al [76] , its predictions are far from the observed results. Based on the VO 2 max and body mass of Miguel Indurain, a professional cyclist, the distance covered in 1 hour predicted by the Accepted Article whereas ranges for world-class athletes are 5-6 l/min [67;77;78] . This and another model [79] both rely on VO 2 max as the most important determinant for endurance performance and describe the relationship as being proportionally curvilinear, meaning that the better the athlete is trained, a similar increase in VO 2 max leads to a proportionally smaller increase in performance. This also demonstrates that in world-class athletes, an increase in VO 2 max will have only limited effect on performance. The failure of such a model [75] to predict 1-hour performance [76] suggests that factors other than VO 2 max are limiting in endurance performance at this level of performance.
Lactate Threshold (LT)
We therefore now address the importance of LT in determining the performance of endurance athletes.
LT, similar to VT1 or VT, is the intensity of work or VO 2 at which the blood lactate concentration gradually starts to increase [80] . Aerobic enzyme activity is a major determinant of LT, reflected by a decline in activity during a period of detraining accompanying a reduction in LT. [81] Because LT reflects an onset of anaerobic metabolism and the coinciding metabolic alterations [45;53] , LT in turn determines the fraction of maximal aerobic power that can be sustained for an extended period. Several studies show that the VO 2 at this LT is highly related to performance, more so than VO 2 [65;67] . LT reflects a balance between the rate of lactate production in the muscles (and hence the rate of lactate influx to the blood) and clearance from the blood. In this balance
another independent factor appears to play a role in endurance performance; difference in performance (time to fatigue) in cyclists with similar VO 2 max can be explained by %VO 2 max at LT, but an additional increase in performance in some athletes seems to be related to a high muscle capillary density. [45;65] A similar correlation between endurance performance and capillary density was found in another study [67] , and Anderson et al [84] found that capillary density increases with training. This might indicate these athletes have a higher capacity to remove and recycle muscle fatiguing metabolites allowing muscles to better tolerate lactic acid production and anaerobic metabolism [85] , or maintain/elongate mean transit time of the blood to increase oxygen extraction [86] .
Lactate Turn Point (LTP)
LTP is a distinct factor related also to lactate [52] . Respiratory compensation point (RCP) [87] , second ventilatory threshold (VT2) or the onset of blood lactate accumulation (OBLA) [88] are related measures.
These factors represent a level of high work intensity at which lactate concentrations show a sudden and sustained rise and hypocapnic hyperventilation occurs. [63;68] This threshold is notably high in professional cyclists and an important factor during extreme endurance events. [64;83] 
Economy (C)
The third main factor contributing to endurance performance is assumed to be completely independent of VO 2 max and lactate-related factors and is called work economy or efficiency (C). It is the ratio between work output (speed, power) and oxygen cost. Running economy is commonly defined as the steady-rate VO 2 in millilitres per kilogram per minute at a standard velocity, cycling economy as the caloric expenditure at a given work rate. Several physiological and biomechanical factors influence C in trained or elite athletes. These include metabolic adaptations within the muscle such as increased mitochondria and oxidative enzymes, the ability of the muscles to store and release elastic energy by altering the mechanical properties of the muscles, and more efficient mechanics leading to less energy wasted on braking forces and excessive vertical oscillation [44] . C is a discriminator of endurance performance independently of VO 2 max in runners [48;68;91-93] and cyclists [63;69;78] , becoming more Accepted Article and C then determines how much speed or power is achieved for a given energy consumption. The relative importance of each of these factors differs at different levels of training. Moderately trained athletes can easily improve all factors, whereas increasing performance in elite athletes is mainly governed by changes in LT, LTP and C. Additional factors including capillary density, heart rate and heart volume, muscle mass and breathing pattern can also influence endurance performance.
Studying the effects of rHuEPO on endurance performance Search strategy
Several studies have addressed the effects of rHuEPO with regards to endurance performance in subjects other than patients. A literature search was conducted in PubMed to identify these papers, using combinations of the key words 'erythropoietin', 'athletic performance', 'physical endurance', 'doping in sports' and 'athletes' for the primary search. Literature references in key papers were examined manually to identify additional papers. We did not attempt to derive quantitative systematic conclusions from a meta-analysis, therefore this could be termed a qualitative systematic review.
Study population mismatch with professional cyclists
Some of the identified studies included "(endurance trained) recreational athletes" or "well trained individuals", others "healthy normal subjects". This raises a problem when interpreting these studies. No standard, such as that proposed by Jeukendrup et al [77] , has been used to classify the cycling abilities of the subjects, and included subjects vary in baseline endurance performance and fitness level within a study and between studies. The level of training of the subjects is poorly reported, but when trying to classify cycling ability [77] using the scarce information reported, based on maximal power output and VO 2 max (absolute and per kg body weight) subjects in these studies would be either "untrained cyclists" [104] [105] [106] [107] [108] [109] [110] or "trained cyclists" [111] [112] [113] [114] [115] or "unclassifiable" [116] . It is, however, clear that in no study reported subjects are at a "competing" level of cycling performance. This highlights a very problematic aspect, which is that the studies do not use well-trained cyclists, still less elite or world-class cyclists, who, would be expected [77] to have VO 2 max values above 70 ml/kg/min (5 l/min) and power outputs above 5 W/kg. Figure 1 compares the studied subjects with these reference values. In the only study using subjects with mean power outputs above 5W/kg the mean VO 2 max is only ~64 ml/kg/min [111] .
The studied subjects may not have reached a plateau in VO 2 max, confounding the interpretation as explained above. Cyclists classified as "well-trained" or higher differ in factors contributing to endurance performance from "trained" or "untrained" cyclists.[45;77;117] VO 2 kinetics are very different even between "well-trained" and "world-class" cyclists [63] . Additionally, this classification shows that there are major discrepancies between the groups in training status, which makes comparison difficult.
Hopkins et al [118] state that: "the results of a research study apply with reasonable certainty only to populations that have similar characteristics to the sample under study. Elite athletes almost certainly have genetic endowment, training history, and training programs that differ from those of subelite athletes. A treatment may therefore produce different effects on performance in these two groups. It follows that the subjects in a study have to be elite athletes for the results to apply convincingly to elite athletes." Therefore it cannot be assumed that effects found in these rHuEPO studies on healthy untrained or trained individuals automatically apply to well-trained, elite and world-class cyclists.
rHuEPO dosing
The doses of rHuEPO in all studies vary, but all are subcutaneous injections, most in a similar range of 150 IU/kg per week (Table 1) . Almost all studies used forms of rHuEPO with half-lives similar to endogenous EPO, namely Eprex® [109-111;113;114;116] , Neorecormon® [104] [105] [106] [107] , Recormon® [115] or it was not reported [112] . Only one study used rHuEPO with a longer half-life, NESP [108] of these studies were reported to be double-blinded, controlling for any bias due to expectation of a positive treatment-effect which is potentially of major influence on exercise tests performed in the studies, whose outcome depends on perseverance and hence motivation. As the study using NESP as rHuEPO treatment is not placebo controlled and does not measure any performance parameters during normoxia, it is difficult to draw conclusions about the effects of this form of rHuEPO on endurance performance. Moreover, the newest form of rHuEPO, CERA, to our knowledge has not been studied for effects on endurance performance in athletes yet at all.
Haematological effects of rHuEPO
Although doses differ somewhat across the studies, most studies report similar effects on haematological parameters albeit with a suggestion of dose-related effect. plasma volume, thereby resulting in almost no effect on, or a slight decrease in BV [123] . rHuEPO could therefore counteract the plasma volume expansion of endurance training [56] . Nevertheless, the combination of effects seems to increase the performance parameter VO 2 max, at least in the studied subjects under laboratory conditions.
Effects on VO2max
The most important question is then whether these effects on haematological parameters translate into an effect on performance. The different parameters that determine endurance performance were discussed previously, but unfortunately most studies only examine one of these parameters, namely VO 2 max. In the reported studies this parameter is increased in the rHuEPO treated subjects, with a relatively constant value for all studies, independent of training status of the subjects, between 7% and 9.7% (Table 1) . Absolute values of VO 2 max and treatment effects can be seen in Figure 1 . This increase in VO 2 max has been reported to be accompanied by an increase in power output [105;106;110;111;114] . This, in turn, resulted in an increase in performance estimated by a time-to-exhaustion test of 22% [106] and 54.3% [105] in untrained subjects and a smaller increase of 9.4% (versus 1.5% in placebo-treated subjects) [115] and 16.6% [112] , in trained subjects. Importantly this surrogate parameter (time-toexhaustion) is measured in a test lasting about 20 minutes and leading to exhaustion, quite different from the required ~5 hour performance in a cycling race.
Does it translate to cycling performance?
As mentioned earlier, VO 2 max is poorly related to cycle performance [64;74] and Lucia et al [124] even questions whether VO 2 max is the limiting factor for maximal endurance performance in some 50% of professional cyclists due to a lack of plateau in VO 2 max during an exercise to exhaustion test. Additionally, time to exhaustion protocols like the ones used here are subject to high variability and poor reproducibility [125;126] , whereas time trial protocols would give a better performance evaluation [125] , also eliminating the influence of wrongly extrapolating laboratory test setting results to race-events [118] . The use of rHuEPO in these subjects clearly has an effect on VO 2 max, which might improve performance at peak intensity during severe exercise, although evidence for this is rather "soft". Apart from the uncertainty whether these same effects can be observed in well-trained or elite cyclists, surprisingly little is known from these studies about effects on submaximal intensities. This might be of major importance when looking at the nature of cycling. Long exercise times during consecutive days with the finish line as a known endpoint (contrary to the "open end" of time to exhaustion tests) makes it crucial for cyclists to distribute their power during a race. This combined with (team) tactics, the terrain and the effects of drag force mean that cyclists only work a small amount of time at their peak intensities, or even above intensities where lactate accumulation occurs.
Investigations in world-class cyclists show that during 3-wk races the subjects' HR is above such an intensity (HR OBLA ) only 3.6% (119 sec) of the time climbing a "Hors Categorie" climb (hardest climb), even less so during first and second category climbs, 2.6% (45 sec) and 2.5% (22 sec) respectively. [90] Similar low percentages were reported by Lucia et al [127] for total race time with HR above the RCP (at 90% VO 2 max) during the Tour de France or Vuelta a España, 2.7% (149 min) and 3.3% (166 min) respectively.
For time trials a difference in time spent with a HR above OBLA was found between different type of time trials, with prologue, short, long and uphill time trials recording 59, 38, 3.5 and 0% for cyclists going all-out. [128] HR values corresponding to physiological markers of performance (e.g. LT, VT2) are stable during a training year in professional cyclists. [83] Other endurance performance parameters unstudied For the major part of a race, cyclists therefore exercise well below their VO 2 max levels, but this parameter still has attracted the most attention when looking at rHuEPO effects. Some studies that Accepted Article evaluated other parameters observed no change in the VO 2 -kinetics [105;106;110;129] or VO 2 at submaximal exercise [112] , despite the increased oxygen carrying capacity due to the increase in [Hb] and Hct. This would mean that the oxygen carrying capacity of the blood does not determine VO 2 kinetics, but that this is regulated and limited by factors in the muscles rather than oxygen supply. This would also indicate that there is no change in LT in these subjects resulting from rHuEPO treatment as shown by Wilkerson et al [106] , who found no effect on gas exchange threshold (GET), a measure closely related to LT, due to the rHuEPO treatment. However, other researchers did find an increase in VT of 14.3% [114] , although this trial was not placebo controlled, so training and placebo effects cannot be accounted for. Another group [111] using a placebo controlled blinded study also found an increase in VT of 12.6%. No conclusive evidence for effects of rHuEPO on LT/VT is therefore available, with evidence on another important lactate parameter, LTP/OBLA/VT2/RCP, completely absent. It is important to elucidate the effects of rHuEPO on these parameters, as performance in cycling is much better related to these factors. [64;74] Time trial world record performance (1-hour world record) for example, seems to be best correlated to and predicted by the speed or power output at OBLA. [76] Other groups also report that performance in longer time trials is highly correlated to power output at OBLA [130] or power output at LT [131] , or with VO 2 at VT1 [132] or LT [67] . In >50km time trials during the Tour the France, performance was correlated with power output at VT1 [133] . In these time trials VO 2 max is not related to performance, which was only demonstrated in shorter time trials (20 min) [131] . Lastly, also uphill cycling has been correlated best to power outputs at LT or OBLA. [130] . This means that the most determining disciplines for the general classification in stage-races in professional cycling are correlated to submaximal exercise parameters.
In the reviewed rHuEPO studies, economy (C), was only measured by one group [105] and did not change after rHuEPO treatment. This would be expected from the non-haematological, bio-mechanical factors that determine C as discussed previously. There is, however, some evidence that prolonged exposure to (Type II) fibres, possibly leading to improved C. [134] More evidence is needed to draw conclusions about effects of rHuEPO on C. Especially when Lance Armstrong, accused of having the biggest doping (e.g. rHuEPO)
network in the history of sports, was reported to have a high muscular efficiency partly contributing to his world-class performance. [69] Some other parameters, such as blood lactate, end-exercise HR and HR kinetics were investigated and reported as not altered by rHuEPO treatment [106] , although other studies indicate a non-significant drop in blood lactate [110] and HR [110;111] or significant in heart rate [114] , although only at submaximal exercise [112] . A significant drop in blood lactate at rest and 10 min into a TTE test, but not at exhaustion [105] was seen. Blood volume was also not affected [112;123] . One blinded study looked at the effect of rHuEPO on perception of physical well-being and reported a positive effect on perceived physical condition and strength [113] which on the basis of evidence are unlikely to be related to an increased muscular mass or improved vascularisation. In a publication [136] from the same study performed by Thomsen et al [105] no effects of prolonged rHuEPO treatment on capillarization or muscle fibre hypertrophy in healthy volunteers were reported. Although this is contrasted by an animal study showing that overexpression of EPO resulted in 14% higher muscle volume and 25% increase in muscle vascularisation, even these effects did not translate to increased muscle force or stamina. [135] .
Alternative mechanisms by which EPO works?
It may be argued that focusing on direct endurance measures does not take into account possible mechanisms by which rHuEPO causes better recovery after exercise. rHuEPO may have antiinflammatory effects and may mitigate ischemia-reperfusion related damage [137] [138] [139] [140] , which could potentially improve recovery. It has been suggested that EPO and its receptor function as a paracrine/autocrine system to mediate the protection of tissues subjected to (metabolic) stress. [141] However, these effects have been not been confirmed in properly designed clinical trials. In fact, most clinical trials focusing on postulated tissue protective effects of rHuEPO have shown adverse rather than beneficial effects. Serious untoward effects have also been shown in rHuEPO-treated patients with stroke, myocardial infarction, acute kidney injury and surgery [142] , compatible with a pro-coagulant state and / or an augmentation of acute inflammation [143] . The data therefore do not suggest substantial beneficial effects on recovery of muscle injury during exercise.
Thus, except on VO 2 max, no coherent or reproducible findings have been reported for both erythropoietic and non-erythropoietic effects of rHuEPO, rendering the evidence too weak to support any conclusion about effects on performance in professional cyclists.
Lack of scientific evidence
Because 1) most of the research with rHuEPO on endurance performance has focused on a parameter for maximal exercise, VO 2 max, 2) the factors that make professional and world-class cyclists unique are not VO 2 max, but LT, RCP and C, 3) endurance performance in professional cycling such as in time trials is best correlated with submaximal exercise factors (e.g. LT, VT1, OBLA, RCP), 4) only small parts of professional cycling races are cycled at severe or maximal intensities (above OBLA/RCP) and 5) the characteristics of the study populations differed from the population suspected of rHuEPO abuse, it cannot be concluded that rHuEPO use enhances performance in professional or elite cyclists.
A more scientific approach needed
Summarizing, the available literature lacks the appropriate information, validity and robustness to conclude that rHuEPO enhances world-class cycling performance. To be able to make such statements, more thorough research needs to be conducted looking at the effects of rHuEPO on submaximal performance parameters and the cycling economy, preferably in a population with cycling performance and unintentionally stimulates its abuse [144] , although it should also be recognized that there is no convincing evidence that any drug works in this context.
rHuEPO adverse effects in athletes
Apart from creating a level playground for all athletes by banning and trying to prevent doping use, doping is also forbidden to protect the athletes from using possibly harmful substances. The presented rHuEPO studies in healthy or trained subjects do not focus on adverse effects. A significant rise in systolic blood pressure (SBP) at rest or during submaximal exercise [112;129] was reported. The number of subjects and treatment times in the presented studies are too small to detect rare adverse events.
Larger studies, namely patient studies, must be consulted for this, although it must be kept in mind that results of these studies do not per se translate to well-trained athletes. One patient study was prematurely discontinued due to increased incidence of thrombotic events in rHuEPO treated metastatic breast cancer patients. [145] Other trials and meta-analyses showed a similar trend in different groups of patients treated with rHuEPO compared to placebo [146] [147] [148] . These studies used ~4 times higher doses of rHuEPO (usually in the range of 40.000 IU or 600 IU/kg per week) compared to the endurance performance studies in healthy subjects. The increased blood viscosity in treated anaemic patients [122;149] , the previously described rise in blood pressure and enhanced coagulation [150] , endothelial activation and platelet reactivity [151] and inflammation [152] after rHuEPO treatment have been evoked to explain these thrombotic events. Acute exercise on itself also enhances coagulation [153] , although this is less pronounced in trained than in untrained subjects. Because plasma volume and blood volume are reduced in acute exercise, Hct is increased [120] . This is even more pronounced in dehydrated and hyperthermic exercise conditions [154;155] . This combination of factors To summarize: published case reports have linked adverse effects to rHuEPO use in cyclists. Patientstudies indicate that rHuEPO has several cardiovascular effects, raising the risk of thrombotic events, encephalopathy and other complications. These risks might plausibly be higher in cyclists because the circumstances in this sport could compound these risks. Also, secrecy due to illicit use in sports might lead to bad handling and storage of the rHuEPO, plausibly elevating the risks of side-effects such as red cell aplasia.
Cyclists and rHuEPO: a risky choice to what advantage?
As the case of the United States Anti Doping Agency versus Armstrong proves again, rHuEPO has been used by many professional (including champion) cyclists. As it increases Hct, it is thought to enhance performance in professional cycling and has been put on the list of prohibited substances of the International Olympic Committee. Because rHuEPO is on this list, cyclists caught were breaking the rules and should be punished for doing so. However, this review shows that only very weak scientific evidence exists about the effects of rHuEPO on cycling performance in professional or even well-trained cyclists.
Sport physicians and cyclists should be informed about the dangers of the use of such a substance, as already proposed by Kuipers about doping in general [144] . Neither a scientific basis for performance enhancing properties, nor possible harmful side-effects have been provided for athletes or trainees.
The situation with rHuEPO use in athletes is analogous to the many forms of non-evidence based treatments that exist in medical practice and which by common opinion should be refuted or confirmed by good clinical trials with real life endpoints. A single well controlled trial in athletes under real life circumstances would give a better indication of the real advantages and risk factors of rHuEPO use, but it would be an oversimplification that this would eradicate its use, even if no benefit was seen with increased biomarkers of risk.
High quality scientific evidence is always preferable to the current situation in which athletes risk their career and health with irrational use of a substance. If the size of the athletic benefit would be shown to be large (which on the basis of the evidence presented in this review is unlikely) it would support the enormous and apparently largely ineffective efforts currently made to detect and prevent the use of rHuEPO. If the effect was small these efforts could be directed elsewhere. Accepted Article
